Among these kinases, the inhibition of TRKC is noteworthy as chromosomal rearrangement mutations involving NTRK genes lead to chimeric proteins with an oncogenic potential in some rare forms of AML and solid cancers [45]. The gene discussed is NTRK3; the disease is acute myeloid leukemia.